Anavex Life Sciences Corp (AVXL)

[imho]

re: what else can AVXL present at CTAD,

Inclusion/exclusion criteria based upon KEM analysis extended by DNA/RNA profiling along with gut biome data.

As a PR bonus following CTAD perhaps Part C longitudinal data and update on how the patients are doing now. As extra bonus more concrete information on trial start.

What have I missed or what else could it be?

Good post and I agree. I like OFP's form of skepticism, but I think the hype is from posters on MB not from the company. Anyone looking for confirmation of efficacy or lack thereof will be disappointed and find the presentation incomplete.

edit: another good post by basparks79

How about knowing the reasons for low blood concentrations or why the ones with high blood concentrations didn't respond well? And perhaps how they will be addressed? Knowing how to select patients for certain success will be a huge value to the company and investors.

IMHO